07.13.21
Curia, formerly AMRI, a contract research, development and manufacturing organization, has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish company headquartered in Camarillo, CA.
The transaction, subject to customary closing conditions, is expected to close in the third quarter. Financial details were not disclosed.
Integrity Bio has expertise in hard-to-formulate biologics and fill-finish of unique therapies in preclinical and clinical development. In a typical year, the company formulates more than 60 large molecules including proteins, antibodies, lipid nanoparticles, peptides and vaccines in liquid and lyophilized form. The company recently expanded its facilities to include a second state-of-the-art fill-finish line, which more than doubled manufacturing capacity.
Integrity Bio’s biologic capabilities enhances Curia’s existing business and will enable Curia to expand its ability to meet customers’ needs. Curia currently provides customers with integrated solutions from formulation development through fill-finish commercial manufacturing across three facilities in Albuquerque, NM; Burlington, MA and Glasgow, Scotland.
“Curia has decades of experience in managing complexity from R&D through manufacturing,” said Curia Chairman and CEO John Ratliff. “I’m looking forward to welcoming the Integrity Bio team. The addition of Integrity Bio is a great fit with our growth strategy and our existing expertise, enhancing our biologics drug product formulation development as well as our fill-finish network. Integrity Bio also adds West Coast coverage to Curia’s East Coast and European capabilities. Together, we can make an even bigger impact on patients’ lives.”
“We are very excited about this transaction; the strategic fit is sound,” said Michael Reilly, CEO of Integrity Bio. “As part of Curia, we can now offer our customers not only world-class formulation and fill-finish but also world-class commercial manufacturing.”
The transaction, subject to customary closing conditions, is expected to close in the third quarter. Financial details were not disclosed.
Integrity Bio has expertise in hard-to-formulate biologics and fill-finish of unique therapies in preclinical and clinical development. In a typical year, the company formulates more than 60 large molecules including proteins, antibodies, lipid nanoparticles, peptides and vaccines in liquid and lyophilized form. The company recently expanded its facilities to include a second state-of-the-art fill-finish line, which more than doubled manufacturing capacity.
Integrity Bio’s biologic capabilities enhances Curia’s existing business and will enable Curia to expand its ability to meet customers’ needs. Curia currently provides customers with integrated solutions from formulation development through fill-finish commercial manufacturing across three facilities in Albuquerque, NM; Burlington, MA and Glasgow, Scotland.
“Curia has decades of experience in managing complexity from R&D through manufacturing,” said Curia Chairman and CEO John Ratliff. “I’m looking forward to welcoming the Integrity Bio team. The addition of Integrity Bio is a great fit with our growth strategy and our existing expertise, enhancing our biologics drug product formulation development as well as our fill-finish network. Integrity Bio also adds West Coast coverage to Curia’s East Coast and European capabilities. Together, we can make an even bigger impact on patients’ lives.”
“We are very excited about this transaction; the strategic fit is sound,” said Michael Reilly, CEO of Integrity Bio. “As part of Curia, we can now offer our customers not only world-class formulation and fill-finish but also world-class commercial manufacturing.”
